GlassScriptPhysician profile
Jeffrey Nestler
NPI 1275637886
$6,936.02
in general payments reported to CMS, 2019-2025
34 companies · $1,246 in 2025
The $1,246 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $712 · 2020: $94.07 · 2021: $223 · 2022: $361 · 2023: $2,455 · 2024: $1,846 · 2025: $1,246.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,596 · Travel and Lodging: $737 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $214.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,595.89 |
| Travel and Lodging | $736.75 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $214.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gastrogpo, LLC | $1,165.00 | 2023 | |
| Abbvie INC. | $900.42 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $606.96 | 2019-2025 | Entyvio, Gattex, Livtencity |
| Janssen Biotech, INC. | $601.58 | 2019-2025 | Tremfya, Stelara, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $489.01 | 2019-2025 | Xifaxan, Trulance |
| Celgene Corporation | $466.45 | 2021-2024 | Zeposia |
| Pfizer INC. | $361.75 | 2019-2024 | |
| Intercept Pharmaceuticals, INC. | $208.59 | 2019-2025 | Ocaliva |
| Boston Scientific Corporation | $186.02 | 2019-2024 | Apollo 2-0 Polypropylene Endobariatric Suture |
| Genzyme Corporation | $182.92 | 2023-2024 | |
| Lilly USA, LLC | $181.39 | 2024-2025 | Omvoh |
| Fujifilm Healthcare Americas Corporation | $175.38 | 2024 | Fujifilm, Utaswako Afp-L3 |
| Madrigal Pharmaceuticals | $163.15 | 2025 | Rezdiffra |
| Gilead Sciences, INC. | $159.77 | 2019-2025 | |
| Ironwood Pharmaceuticals, INC | $159.65 | 2023 | Linzess |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cardinal Health 110 LLC | $136.55 | 2025 | |
| Olympus America INC. | $111.75 | 2023 | |
| Medtronic, INC. | $108.10 | 2023-2024 | Barrx, Beacon |
| Janssen Scientific Affairs, LLC | $103.40 | 2023 | Tremfya, Stelara |
| Regeneron Healthcare Solutions, INC. | $88.75 | 2023-2025 | Dupixent |
| Ardelyx, INC. | $66.24 | 2023-2024 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $39.97 | 2024-2025 | Voquezna |
| Ipsen Biopharmaceuticals, INC | $38.27 | 2023 | Bylvay |
| Echosens North America, INC. | $35.00 | 2019 | |
| Novo Nordisk INC | $34.24 | 2025 | Wegovy |
| Amgen INC. | $31.08 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $24.98 | 2019 | |
| Nestle Healthcare Nutrition INC. | $18.88 | 2023 | |
| Merck Sharp & Dohme LLC | $18.75 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $16.14 | 2022 | |
| Ucb, INC. | $15.84 | 2019 | |
| Alcresta Therapeutics, INC. | $15.00 | 2019 | |
| Evoke Pharma, INC. | $13.15 | 2024 | |
| Allergan, INC. | $11.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$77,759.52 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Nestler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.